# HER2-positive breast cancer

Source: https://onco.cc/cancers/breast-her2-positive/  
OnCo record `breast-her2-positive` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu.

## Summary

HER2-positive breast cancer (15-20% of cases; HER2 IHC 3+ or ISH-amplified) was the most aggressive subtype until trastuzumab (1998) made it one of the most treatable. The modern curative pathway is response-adapted: neoadjuvant chemotherapy with dual HER2 blockade (or, since 2026, T-DXd followed by THP), surgery, then either antibody completion for patients with a pathologic complete response or an ADC for residual disease (T-DM1 from KATHERINE, now T-DXd from DESTINY-Breast05). Small node-negative tumours are cured with paclitaxel-trastuzumab alone; PHERGain showed that an early PET response can spare a third of patients chemotherapy altogether. Extended adjuvant neratinib and adjuvant pertuzumab add small gains in higher-risk, node-positive disease.

Metastatic disease has been transformed twice: by CLEOPATRA's pertuzumab (OS 57 months) and then by trastuzumab deruxtecan, which beat T-DM1 by a wide margin in second line (DESTINY-Breast03) and beat THP in first line (DESTINY-Breast09, PFS 40.7 months; approved 2025). Brain metastases, which develop in up to half of patients, are now treatable systemically with tucatinib (HER2CLIMB) and T-DXd (DESTINY-Breast12). HER2CLIMB-05 (tucatinib maintenance) and PATINA (palbociclib maintenance in HR+/HER2+, approved 2026) intensify chemotherapy-free maintenance, and a wave of Chinese HER2 ADCs (trastuzumab rezetecan, BL-M07D1, ARX788, disitamab vedotin) is producing Enhertu-scale results.

Open problems are the sequencing of HER2 ADCs after T-DXd (payload cross-resistance), interstitial lung disease, cardiotoxicity across years of therapy, the cost and duration of antibody therapy, brain metastases prevention, and de-escalation: identifying the substantial fraction of patients who are over-treated. The pipeline is defined by T-DXd's move into every curative setting, tucatinib-based maintenance, next-generation and biparatopic HER2 ADCs (zanidatamab zovodotin), HER2 CAR-T and vaccines, and imaging- and ctDNA-adapted de-escalation trials.

## Fields

- Kind: Cancer
- Last checked: 2026-09-07
- Tags: breast; spike
- Group: breast
- Burden: 15-20% of breast cancers (roughly 400,000 cases per year worldwide). Ten-year survival for early-stage disease treated with trastuzumab-based therapy exceeds 80%.
- Subtypes: HER2-enriched (PAM50; highest pCR rates to HER2 blockade); HR+/HER2+ ('triple-positive', ~50% of HER2+; lower pCR, endocrine therapy and CDK4/6 maintenance relevant); HR-/HER2+ (higher pCR, more relapse in first 3 years); HER2-mutant (activating mutations without amplification; T-DXd tumour-agnostic, HER2 TKIs; more common in lobular and HER2-low); HER2 heterogeneous tumours (mixed amplified and non-amplified clones; lower pCR); Small node-negative (stage I) disease cured by de-escalated therapy
- Biomarkers: HER2 IHC 3+ or ISH-amplified; HR status; pCR after neoadjuvant therapy; HER2 IHC 3+ or IHC 2+ with ISH amplification (ASCO/CAP 2018 criteria); HER2 heterogeneity; HR status (drives triple-positive management, PATINA eligibility); Pathologic complete response after neoadjuvant therapy (selects T-DM1/T-DXd post-neoadjuvant); Early FDG-PET response (PHERGain de-escalation); LVEF by echocardiography or MUGA every 3 months on anti-HER2 therapy; Brain MRI when symptomatic; surveillance MRI debated; HER2 status on re-biopsy at progression (conversion in 10-15%); PIK3CA mutation (lower pCR; INAVO122 tests inavolisib in HER2+); ctDNA MRD (investigational for post-neoadjuvant escalation)

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/breast-her2-positive/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/breast-her2-positive/#overview [2 subtypes, 8 state-of-the-art points]
- What it is (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/breast-her2-positive/#what-it-is [8 subtypes, 5 sites of spread]
- Finding it (on the hub): How it shows itself, how it is confirmed, what screening exists, and the biomarkers clinicians test for. https://onco.cc/cancers/breast-her2-positive/#finding-it [12 biomarkers, 2 prevalence rows]
- Treating it (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/breast-her2-positive/#treating-it [12 settings, 10 regimens, 11 decisions with options]
- Evidence (own page): Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/breast-her2-positive/evidence/ [93 trials, 19 key papers, 20 milestones]
- The science (on the hub): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/breast-her2-positive/#science [11 targets, 6 pathways, 5 preclinical models]
- Where you are (own page): Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record. https://onco.cc/cancers/breast-her2-positive/where-you-are/ [20 centres]
- Living with it (own page): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/breast-her2-positive/living-with-it/ [43 questions, 6 red cards]
- What is coming (own page): Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/breast-her2-positive/coming/ [38 medicines, 93 trials, 20 ideas, 10 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/breast-her2-positive/data/ [395 connected records]

## Standard of care

- Early stage: Neoadjuvant THP or T-DXd → surgery → trastuzumab/pertuzumab (pCR) or T-DXd/T-DM1 (residual). ([Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/), [DESTINY-Breast11](https://onco.cc/trials/destiny-breast11/))
- Metastatic: T-DXd + pertuzumab first line (DESTINY-Breast09); tucatinib + trastuzumab + capecitabine for brain metastases; palbociclib maintenance if HR+. ([DESTINY-Breast09](https://onco.cc/trials/destiny-breast09/), [Tucatinib](https://onco.cc/drugs/tucatinib/), [Palbociclib](https://onco.cc/drugs/palbociclib/))
- Stage I (≤2-3 cm, node-negative): Surgery then weekly paclitaxel × 12 + trastuzumab × 1 year (APT); T-DM1 × 17 cycles is an alternative (ATEMPT). Endocrine therapy if HR+. ([APT (adjuvant paclitaxel-trastuzumab)](https://onco.cc/trials/apt-trial/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/))
- Stage II-III, neoadjuvant: TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) or anthracycline-taxane + HP; from 2026, T-DXd × 4 → THP (DESTINY-Breast11, pCR 67%). PET-adapted chemotherapy omission (PHERGain) in trials. ([DESTINY-Breast11](https://onco.cc/trials/destiny-breast11/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [PHERGain](https://onco.cc/trials/phergain/))
- Post-neoadjuvant, pathologic complete response: Complete 1 year of trastuzumab (± pertuzumab if node-positive at diagnosis); endocrine therapy if HR+; radiation per stage. ([Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [APHINITY](https://onco.cc/trials/aphinity/), [HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)](https://onco.cc/trials/hera-b31-n9831/))
- Post-neoadjuvant, residual invasive disease: T-DXd (DESTINY-Breast05, iDFS HR 0.47 vs T-DM1; approved 2026) replacing T-DM1 (KATHERINE); consider extended adjuvant neratinib for HR+ high-risk. ([DESTINY-Breast05](https://onco.cc/trials/destiny-breast05/), [KATHERINE](https://onco.cc/trials/katherine/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/), [Neratinib](https://onco.cc/drugs/neratinib/))
- Adjuvant (upfront surgery), node-positive: Chemotherapy + trastuzumab + pertuzumab for 1 year (APHINITY); trastuzumab alone for lower risk; 6 months acceptable where resources are limited (PERSEPHONE). ([APHINITY](https://onco.cc/trials/aphinity/), [PERSEPHONE](https://onco.cc/trials/persephone/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/))
- Metastatic, first line: T-DXd + pertuzumab (DESTINY-Breast09, PFS 40.7 months; approved 2025) or taxane + trastuzumab + pertuzumab (CLEOPATRA) followed by maintenance: HP ± tucatinib (HER2CLIMB-05) and, if HR+, endocrine therapy + palbociclib (PATINA, approved 2026). ([DESTINY-Breast09](https://onco.cc/trials/destiny-breast09/), [CLEOPATRA](https://onco.cc/trials/cleopatra/), [HER2CLIMB-05](https://onco.cc/trials/her2climb-05/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Tucatinib](https://onco.cc/drugs/tucatinib/), [Palbociclib](https://onco.cc/drugs/palbociclib/))
- Metastatic, second line: T-DXd if not used first line (DESTINY-Breast03, PFS HR 0.33 vs T-DM1); tucatinib + trastuzumab + capecitabine, especially with brain metastases (HER2CLIMB). ([DESTINY-Breast03](https://onco.cc/trials/destiny-breast03/), [HER2CLIMB](https://onco.cc/trials/her2climb/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Tucatinib](https://onco.cc/drugs/tucatinib/))
- Metastatic, later lines: T-DM1; neratinib or lapatinib + capecitabine; margetuximab + chemotherapy; trastuzumab + chemotherapy (continued HER2 blockade); zanidatamab and Chinese ADCs (trastuzumab rezetecan, disitamab vedotin) where available; trials. ([Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/), [Neratinib](https://onco.cc/drugs/neratinib/), [Lapatinib](https://onco.cc/drugs/lapatinib/), [Margetuximab](https://onco.cc/drugs/margetuximab/), [Zanidatamab](https://onco.cc/drugs/zanidatamab/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/), [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/))
- Brain metastases: Systemic: tucatinib triplet or T-DXd (DESTINY-Breast12, intracranial ORR 72%); local: stereotactic radiosurgery or surgery for symptomatic or large lesions; whole-brain RT reserved. ([HER2CLIMB](https://onco.cc/trials/her2climb/), [DESTINY-Breast12](https://onco.cc/trials/destiny-breast12/), [Tucatinib](https://onco.cc/drugs/tucatinib/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/))
- Cardiac monitoring and survivorship: LVEF every 3 months during anti-HER2 therapy; hold and cardioprotect for declines; anthracycline-free regimens preferred; long-term surveillance for late recurrence in HR+/HER2+. ([Cardio-oncology](https://onco.cc/technologies/cardio-oncology/), [PERSEPHONE](https://onco.cc/trials/persephone/))

## State of the art

- T-DXd across the disease continuum.
- Chemotherapy de-escalation guided by early response.
- Ten-year survival above 80% for early disease: the subtype with the poorest outlook in the 1990s is now one of the most treatable.
- Response-adapted curative therapy: pCR patients de-escalate, residual disease escalates to an ADC (now T-DXd, iDFS HR 0.47 vs T-DM1).
- T-DXd across the continuum: neoadjuvant (2026), post-neoadjuvant (2026), first-line metastatic with pertuzumab (2025, PFS 40.7 months), second line, and brain metastases.
- Systemic control of brain metastases (tucatinib, T-DXd) allowing deferral of radiation.
- Chemotherapy-free maintenance intensification: tucatinib (HER2CLIMB-05) and palbociclib for HR+/HER2+ (PATINA).
- Chemotherapy omission for a third of patients using early PET response (PHERGain).

## Open problems

- Brain metastases in ~50% of metastatic patients.
- Which patients can skip chemotherapy entirely.
- Sequencing after T-DXd: no randomised data on which HER2 ADC or TKI works after TOP1-payload failure.
- Interstitial lung disease with T-DXd in curative settings, where patients would otherwise be cured.
- Over-treatment: which patients need pertuzumab, a full year of antibodies, or any chemotherapy at all (PHERGain-2, response-adapted trials).
- Brain metastasis prevention and whether systemic-first strategies preserve cognition.
- HR+/HER2+ ('triple-positive') disease: optimal integration of endocrine therapy, CDK4/6 inhibitors, and HER2 blockade.
- Cardiotoxicity surveillance burden versus event rates in low-risk patients.
- Global access: biosimilars have widened trastuzumab access but pertuzumab, T-DM1, and T-DXd remain unavailable in much of the world.
- HER2 heterogeneity and HER2 conversion at relapse require re-biopsy strategies or HER2 PET.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/HER2-positive_breast_cancer
- Wikipedia: https://en.wikipedia.org/wiki/HER2-positive_breast_cancer

## Connected records

- roadmaps: [ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs](https://onco.cc/roadmaps/adc-generations/), [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- pairings: [Early FDG-PET response → chemotherapy omission (HER2+)](https://onco.cc/pairings/pet-adapted-her2-deescalation/), [Tucatinib + trastuzumab + capecitabine for brain metastases](https://onco.cc/pairings/tucatinib-triplet-brain-mets/)
- cancers: [Apocrine carcinoma of the breast](https://onco.cc/cancers/apocrine-carcinoma-breast/), [Brain metastases (secondary brain tumours)](https://onco.cc/cancers/secondary-brain-tumours/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Ductal carcinoma in situ (DCIS)](https://onco.cc/cancers/ductal-carcinoma-in-situ/), [Early HER2-positive breast cancer](https://onco.cc/cancers/her2-positive-early-breast-cancer/), [HER2-low and HER2-ultralow metastatic breast cancer](https://onco.cc/cancers/her2-low-metastatic-breast-cancer/), [HER2-positive breast cancer with brain metastases](https://onco.cc/cancers/her2-positive-breast-brain-metastases/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Inflammatory breast cancer](https://onco.cc/cancers/inflammatory-breast-cancer/), [Invasive breast carcinoma of no special type (invasive ductal carcinoma)](https://onco.cc/cancers/invasive-breast-carcinoma-no-special-type/), [Invasive micropapillary carcinoma of the breast](https://onco.cc/cancers/invasive-micropapillary-carcinoma-breast/), [Male breast cancer](https://onco.cc/cancers/male-breast-cancer/), [Paget disease of the nipple](https://onco.cc/cancers/paget-disease-of-the-nipple/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [AI scoring of biomarkers and grade on pathology slides](https://onco.cc/technologies/ai-pathology-scoring/), [AI-assisted mammography screening](https://onco.cc/technologies/ai-mammography-screening/), [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Biosimilar manufacturing and comparability](https://onco.cc/technologies/biosimilar-manufacturing/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/), [CDK4/6 inhibitors](https://onco.cc/technologies/cdk46-inhibitor/), [Dietitian-led weight-loss programmes in HR-positive breast cancer](https://onco.cc/technologies/dietitian-led-weight-loss-breast/), [FDG PET](https://onco.cc/technologies/fdg-pet/), [HER2 PET](https://onco.cc/technologies/her2-pet/), [HER2 tyrosine kinase inhibitors](https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/), [Hypofractionated radiotherapy](https://onco.cc/technologies/hypofractionated-radiotherapy/), [Mammography & tomosynthesis](https://onco.cc/technologies/mammography/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Norton-Simon hypothesis and dose-dense chemotherapy](https://onco.cc/technologies/norton-simon-hypothesis/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Scalp cooling (cold caps: DigniCap, Paxman)](https://onco.cc/technologies/scalp-cooling/), [Site-specific conjugation & linker chemistry](https://onco.cc/technologies/site-specific-conjugation/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [Strain echocardiography (global longitudinal strain)](https://onco.cc/technologies/strain-echocardiography-gls/), [Surface-guided radiotherapy (SGRT)](https://onco.cc/technologies/surface-guided-radiotherapy/), [Troponin and natriuretic peptide monitoring during cancer treatment](https://onco.cc/technologies/cardiac-biomarker-monitoring/)
- targets: [BIRC5](https://onco.cc/targets/birc5/), [CDK4/6](https://onco.cc/targets/cdk4-6/), [EGFR](https://onco.cc/targets/egfr/), [FCGR2A](https://onco.cc/targets/fcgr2a/), [FCGR3A](https://onco.cc/targets/fcgr3a/), [HER2](https://onco.cc/targets/her2/), [HER3](https://onco.cc/targets/her3/), [HER4 (ERBB4)](https://onco.cc/targets/erbb4/), [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/), [PTK6 (BRK)](https://onco.cc/targets/ptk6/), [Topoisomerase I (TOP1)](https://onco.cc/targets/top1/)
- drugs: [A166](https://onco.cc/drugs/a166/), [ARX788](https://onco.cc/drugs/arx788/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Epirubicin](https://onco.cc/drugs/epirubicin/), [Evorpacept](https://onco.cc/drugs/evorpacept/), [GQ1005](https://onco.cc/drugs/gq1005/), [HB1801](https://onco.cc/drugs/hb1801/), [HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)](https://onco.cc/drugs/her2-testing-assays/), [HLX11](https://onco.cc/drugs/hlx11/), [IBI354](https://onco.cc/drugs/ibi354/), [Inavolisib](https://onco.cc/drugs/inavolisib/), [Inetetamab](https://onco.cc/drugs/inetetamab/), [JSKN003](https://onco.cc/drugs/jskn003/), [KN026](https://onco.cc/drugs/kn026/), [Lapatinib](https://onco.cc/drugs/lapatinib/), [Margetuximab](https://onco.cc/drugs/margetuximab/), [Neratinib](https://onco.cc/drugs/neratinib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Palbociclib](https://onco.cc/drugs/palbociclib/), [Pegulicianine](https://onco.cc/drugs/pegulicianine/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Pyrotinib](https://onco.cc/drugs/pyrotinib/), [RO7771950](https://onco.cc/drugs/ro7771950/), [RPH-051](https://onco.cc/drugs/rph-051/), [TQB2102](https://onco.cc/drugs/tqb2102/), [Transpara](https://onco.cc/drugs/transpara/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab biosimilars](https://onco.cc/drugs/trastuzumab-biosimilars/), [Trastuzumab brengitecan](https://onco.cc/drugs/trastuzumab-brengitecan/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Trastuzumab duocarmazine](https://onco.cc/drugs/trastuzumab-duocarmazine/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/), [Trastuzumab pamirtecan](https://onco.cc/drugs/trastuzumab-pamirtecan/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/), [Tucatinib](https://onco.cc/drugs/tucatinib/), [Zanidatamab](https://onco.cc/drugs/zanidatamab/), [Zanidatamab zovodotin](https://onco.cc/drugs/zanidatamab-zovodotin/)
- companies: [3SBio](https://onco.cc/companies/3sbio/), [Ambrx](https://onco.cc/companies/ambrx/), [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Ataraxis AI](https://onco.cc/companies/ataraxis-ai/), [Austrian Breast & Colorectal Cancer Study Group](https://onco.cc/companies/abcsg/), [Breast Cancer Trials](https://onco.cc/companies/breast-cancer-trials/), [Breast International Group (BIG)](https://onco.cc/companies/big/), [BridgeBio Oncology Therapeutics](https://onco.cc/companies/bridgebio-oncology-therapeutics/), [Callio Therapeutics](https://onco.cc/companies/callio-therapeutics/), [Clear Gene](https://onco.cc/companies/clear-gene/), [Criterium](https://onco.cc/companies/criterium/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Danish Breast Cancer Group](https://onco.cc/companies/dbcg/), [ETOP IBCSG Partners Foundation](https://onco.cc/companies/etop-ibcsg/), [Galena Biopharma](https://onco.cc/companies/galena-biopharma/), [GEICAM Spanish Breast Cancer Group](https://onco.cc/companies/geicam/), [GeneQuantum Healthcare (Suzhou)](https://onco.cc/companies/genequantum-healthcare-suzhou/), [Ibex Medical Analytics](https://onco.cc/companies/ibex-medical-analytics/), [iSono Health](https://onco.cc/companies/isono-health/), [Jazz Pharmaceuticals](https://onco.cc/companies/jazz/), [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/), [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/), [Kheiron Medical Technologies](https://onco.cc/companies/kheiron-medical-technologies/), [Korean Cancer Study Group](https://onco.cc/companies/kcsg/), [Lumicell](https://onco.cc/companies/lumicell/), [MacroGenics](https://onco.cc/companies/macrogenics/), [NearWave](https://onco.cc/companies/nearwave/), [NSABP Foundation](https://onco.cc/companies/nsabp-foundation/), [Organon & Co.](https://onco.cc/companies/organon/), [Outcomes4Me](https://onco.cc/companies/outcomes4me/), [Perimeter Medical Imaging AI](https://onco.cc/companies/perimeter-medical-imaging-ai/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/), [Precirix](https://onco.cc/companies/precirix/), [Proxygen](https://onco.cc/companies/proxygen/), [Puma Biotechnology](https://onco.cc/companies/puma-biotechnology/), [RemeGen](https://onco.cc/companies/remegen/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/), [Samsung Bioepis](https://onco.cc/companies/samsung-bioepis/), [SOLTI Cancer Research Group](https://onco.cc/companies/solti/), [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/), [Therapixel](https://onco.cc/companies/therapixel/), [Vara](https://onco.cc/companies/vara/), [Volpara Health](https://onco.cc/companies/volpara-health/), [West Japan Oncology Group](https://onco.cc/companies/wjog/), [Zymeworks](https://onco.cc/companies/zymeworks/)
- pathways: [Breast cancer (KEGG map)](https://onco.cc/pathways/breast-cancer-signalling/), [p53 / RB / cell-cycle checkpoint](https://onco.cc/pathways/p53-cell-cycle/), [PI3K / AKT / mTOR](https://onco.cc/pathways/pi3k-akt-mtor/), [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/), [Receptor tyrosine kinase activation](https://onco.cc/pathways/rtk-activation/), [The blood-brain barrier & brain metastasis](https://onco.cc/pathways/blood-brain-barrier-metastasis/)
- terms: [ADC sequencing](https://onco.cc/terms/adc-sequencing/), [AJCC 8th edition prognostic stage for breast cancer](https://onco.cc/terms/ajcc-prognostic-stage-breast/), [Biosimilar](https://onco.cc/terms/biosimilar/), [Brain metastases (intracranial disease)](https://onco.cc/terms/brain-metastases/), [Deauville score and PET-adapted therapy](https://onco.cc/terms/deauville/), [Deep inspiration breath-hold (DIBH)](https://onco.cc/terms/deep-inspiration-breath-hold/), [Dual HER2 blockade](https://onco.cc/terms/dual-her2-blockade/), [HER2-positive (IHC 3+ or ISH-amplified)](https://onco.cc/terms/her2-positive/), [HER2-positive brain metastases](https://onco.cc/terms/her2-brain-metastases/), [Interstitial lung disease (ILD) / pneumonitis](https://onco.cc/terms/ild/), [Lumpectomy (breast-conserving surgery)](https://onco.cc/terms/lumpectomy/), [Mastectomy](https://onco.cc/terms/mastectomy/), [Pathologic complete response (pCR)](https://onco.cc/terms/pcr/), [Trastuzumab cardiotoxicity](https://onco.cc/terms/trastuzumab-cardiotoxicity/)
- trials: [A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer](https://onco.cc/trials/nct07043725/), [A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer](https://onco.cc/trials/nct07003074/), [A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So](https://onco.cc/trials/nct05593094/), [A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer](https://onco.cc/trials/nct04538742/), [A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer](https://onco.cc/trials/nct07102381/), [A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients](https://onco.cc/trials/nct06832202/), [A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer](https://onco.cc/trials/nct06747338/), [A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer](https://onco.cc/trials/nct07441460/), [A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer](https://onco.cc/trials/nct06057610/), [A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy](https://onco.cc/trials/nct06126640/), [A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct07678957/), [A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer](https://onco.cc/trials/nct06316531/), [A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o](https://onco.cc/trials/nct06435429/), [A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy](https://onco.cc/trials/nct04873362/), [A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer](https://onco.cc/trials/nct07299825/), [A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy](https://onco.cc/trials/nct06968585/), [A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M](https://onco.cc/trials/nct07518173/), [A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct06957886/), [A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy](https://onco.cc/trials/nct06830889/), [A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea](https://onco.cc/trials/nct06891833/), [A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive ](https://onco.cc/trials/nct06445400/), [A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Bre](https://onco.cc/trials/nct06018337/), [A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors](https://onco.cc/trials/nct06157892/), [A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer](https://onco.cc/trials/nct06198751/), [A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer](https://onco.cc/trials/nct07386938/), [A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer](https://onco.cc/trials/nct06265428/), [A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer](https://onco.cc/trials/nct07294508/), [A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer](https://onco.cc/trials/nct05346224/), [A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer](https://onco.cc/trials/nct05894239/), [A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer](https://onco.cc/trials/nct07673029/), [A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer](https://onco.cc/trials/nct07196774/), [ACE-Breast-02](https://onco.cc/trials/ace-breast-02/), [APHINITY](https://onco.cc/trials/aphinity/), [APT (adjuvant paclitaxel-trastuzumab)](https://onco.cc/trials/apt-trial/), [ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)](https://onco.cc/trials/nct04829604/), [ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer](https://onco.cc/trials/nct07007559/), [ATEMPT](https://onco.cc/trials/atempt/), [BWEL (Breast Cancer Weight Loss, Alliance A011401)](https://onco.cc/trials/bwel/), [CLEOPATRA](https://onco.cc/trials/cleopatra/), [Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer](https://onco.cc/trials/nct05802225/), [Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.](https://onco.cc/trials/nct05230810/), [Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer](https://onco.cc/trials/nct07008976/), [DBCG 82b and 82c](https://onco.cc/trials/dbcg-82bc/), [DESTINY-Breast03](https://onco.cc/trials/destiny-breast03/), [DESTINY-Breast05](https://onco.cc/trials/destiny-breast05/), [DESTINY-Breast09](https://onco.cc/trials/destiny-breast09/), [DESTINY-Breast11](https://onco.cc/trials/destiny-breast11/), [DESTINY-Breast12](https://onco.cc/trials/destiny-breast12/), [DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer](https://onco.cc/trials/nct06313086/), [Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)](https://onco.cc/trials/nct07486089/), [Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC](https://onco.cc/trials/nct07510802/), [DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer](https://onco.cc/trials/nct06178159/), [Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer](https://onco.cc/trials/nct05838066/), [Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer](https://onco.cc/trials/nct06642545/), [EORTC 22922/10925](https://onco.cc/trials/eortc-22922/), [FAST-Forward](https://onco.cc/trials/fast-forward/), [HER2CLIMB](https://onco.cc/trials/her2climb/), [HER2CLIMB-02](https://onco.cc/trials/her2climb-02/), [HER2CLIMB-05](https://onco.cc/trials/her2climb-05/), [HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)](https://onco.cc/trials/hera-b31-n9831/), [HORIZON-Breast01](https://onco.cc/trials/horizon-breast01/), [I-SPY 1 (CALGB 150007/150012, ACRIN 6657)](https://onco.cc/trials/i-spy-1/), [I-SPY 2](https://onco.cc/trials/i-spy-2/), [I-SPY 2.2](https://onco.cc/trials/i-spy-2-2/), [IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer](https://onco.cc/trials/nct07377643/), [IMPORT LOW](https://onco.cc/trials/import-low/), [INSITE](https://onco.cc/trials/insite/), [JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer](https://onco.cc/trials/nct06846437/), [KATHERINE](https://onco.cc/trials/katherine/), [KRISTINE](https://onco.cc/trials/kristine/), [MARGetuximab Or Trastuzumab (MARGOT)](https://onco.cc/trials/nct04425018/), [NALA](https://onco.cc/trials/nala/), [NCIC MA.20](https://onco.cc/trials/ma-20/), [Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer](https://onco.cc/trials/nct06227117/), [NeoSphere](https://onco.cc/trials/neosphere/), [NSABP B-39/RTOG 0413](https://onco.cc/trials/nsabp-b39/), [PATINA](https://onco.cc/trials/patina/), [Peritumoral lidocaine before breast cancer surgery (Tata Memorial)](https://onco.cc/trials/lidocaine-peritumoral-tmh/), [PERSEPHONE](https://onco.cc/trials/persephone/), [PHERGain](https://onco.cc/trials/phergain/), [RADCOMP](https://onco.cc/trials/radcomp/), [RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure](https://onco.cc/trials/nct07366840/), [RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive](https://onco.cc/trials/nct07413939/), [START-B (UK Standardisation of Breast Radiotherapy)](https://onco.cc/trials/start-b/), [Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies](https://onco.cc/trials/nct04561362/), [Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation](https://onco.cc/trials/nct04208178/), [Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)](https://onco.cc/trials/nct06686394/), [TMIST (Tomosynthesis Mammographic Imaging Screening Trial)](https://onco.cc/trials/tmist/), [To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer](https://onco.cc/trials/nct06389006/), [TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer](https://onco.cc/trials/nct07047365/), [TRAIN-2](https://onco.cc/trials/train-2/), [Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer](https://onco.cc/trials/nct05950945/), [TUXEDO-1](https://onco.cc/trials/tuxedo-1/)
- journals: [Breast cancer](https://onco.cc/journals/breast-cancer-jbcs/), [Breast cancer research](https://onco.cc/journals/breast-cancer-research/), [Breast cancer research and treatment](https://onco.cc/journals/breast-cancer-research-and-treatment/), [Clinical breast cancer](https://onco.cc/journals/clinical-breast-cancer/), [Journal of breast imaging](https://onco.cc/journals/journal-of-breast-imaging/), [Journal of mammary gland biology and neoplasia](https://onco.cc/journals/journal-of-mammary-gland-biology-and-neoplasia/), [The Breast](https://onco.cc/journals/the-breast/), [The breast journal](https://onco.cc/journals/the-breast-journal/)
- ideas: [A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy](https://onco.cc/ideas/idea-acc-risk-stratified-cardio-oncology-pathway/), [A standard platform to get drugs into the brain: focused ultrasound plus shuttle-engineered therapeutics](https://onco.cc/ideas/idea-moon-brain-delivery-platform/), [An organotropism atlas that predicts where a cancer will spread](https://onco.cc/ideas/idea-bio2-organotropism-atlas/), [Biomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy](https://onco.cc/ideas/idea-moon-cardioprotection-by-default/), [Brain metastases included by default in every solid-tumour trial](https://onco.cc/ideas/idea-tr1-brain-mets-default-included/), [Build a human model of the barrier that guards the brain fluid](https://onco.cc/ideas/idea-bio2-blood-csf-barrier-model/), [Can T-DXd alone cure early HER2-positive disease?](https://onco.cc/ideas/idea-tdxd-first-then-nothing/), [Deliver CAR-T cells straight into the fluid around the brain](https://onco.cc/ideas/idea-bio2-intraventricular-car-t/), [Fund trials that test shorter courses of the most expensive adjuvant drugs](https://onco.cc/ideas/idea-cost-shorter-course-trials/), [One-stop breast clinics: imaging, biopsy and a preliminary answer in a single visit](https://onco.cc/ideas/idea-acc-one-stop-breast-diagnostic-clinic/), [Prevention trials aimed only at brain metastasis](https://onco.cc/ideas/idea-bio2-brain-met-prevention-trials/), [Public country dashboards for the three WHO breast cancer targets](https://onco.cc/ideas/idea-acc-gbci-country-dashboards/), [Re-test the metastasis, not the old primary, before every change of treatment](https://onco.cc/ideas/idea-bio1-rebiopsy-before-switch/), [Read the spinal fluid to track brain tumours without opening the skull](https://onco.cc/ideas/idea-bio2-csf-ctdna-monitoring/), [Reduce the dose once the cancer responds: response-adapted de-escalation trials](https://onco.cc/ideas/idea-tr1-response-adapted-dose-reduction/), [Sequencing HER2 ADCs by payload after T-DXd](https://onco.cc/ideas/idea-her2-adc-sequencing-payload/), [Systemic-first management of HER2-positive brain metastases](https://onco.cc/ideas/idea-cns-first-adc-strategy/), [Treat brain metastases as a disease with its own trials programme](https://onco.cc/ideas/idea-fund-brain-metastases-programme/), [Use the brain's own transport door to carry antibody drugs across](https://onco.cc/ideas/idea-bio2-transferrin-shuttle-adc/), [WHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator](https://onco.cc/ideas/idea-acc-biosimilar-prequalification-pool/)
- key papers: [Al-Hajj 2003: prospective identification of tumorigenic breast cancer cells](https://onco.cc/key-papers/paper-al-hajj-breast-cancer-stem-cells-pnas-2003/), [Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology](https://onco.cc/key-papers/paper-nccn-breast-cancer-v4-2026-jnccn-2026/), [DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer](https://onco.cc/key-papers/paper-destiny-breast03-nejm-2022/), [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-early-breast-cancer-guideline-ann-oncol-2024/), [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://onco.cc/key-papers/paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021/), [Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications](https://onco.cc/key-papers/paper-sorlie-breast-carcinoma-subclasses-pnas-2001/), [KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment](https://onco.cc/key-papers/paper-katherine-nejm-2019/), [Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype](https://onco.cc/key-papers/paper-symmans-rcb-long-term-prognosis-subtype-jco-2017/), [MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload](https://onco.cc/key-papers/paper-masai-lancet-oncol-2023/), [Molecular portraits of human breast tumours](https://onco.cc/key-papers/paper-perou-molecular-portraits-breast-tumours-nature-2000/), [Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis](https://onco.cc/key-papers/paper-cortazar-ctneobc-pcr-pooled-analysis-lancet-2014/), [Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients](https://onco.cc/key-papers/paper-yau-rcb-pooled-analysis-5161-lancet-oncol-2022/), [SCALP: scalp cooling to prevent hair loss during chemotherapy for early breast cancer](https://onco.cc/key-papers/paper-scalp-trial-jama-2017/), [Slamon 1987: HER2 gene amplification marks an aggressive form of breast cancer](https://onco.cc/key-papers/paper-slamon-her2-amplification-science-1987/), [Slamon 1989: HER2/neu in human breast and ovarian cancer](https://onco.cc/key-papers/paper-slamon-her2-breast-ovarian-science-1989/), [Slamon 2001: adding trastuzumab to chemotherapy for HER2-positive metastatic breast cancer](https://onco.cc/key-papers/paper-slamon-trastuzumab-nejm-2001/), [Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer](https://onco.cc/key-papers/paper-st-gallen-2025-consensus-ann-oncol-2025/), [Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023](https://onco.cc/key-papers/paper-st-gallen-2023-consensus-ann-oncol-2023/), [US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status](https://onco.cc/key-papers/paper-howlader-us-incidence-breast-subtypes-jnci-2014/)
- institutions: [Breast Cancer Research Foundation](https://onco.cc/institutions/bcrf/), [Centre Léon Bérard](https://onco.cc/institutions/centre-leon-berard/), [Champalimaud Foundation, Champalimaud Clinical Centre](https://onco.cc/institutions/champalimaud/), [Duke Cancer Institute](https://onco.cc/institutions/duke-cancer-institute/), [Fondazione Michelangelo](https://onco.cc/institutions/fondazione-michelangelo/), [Georgetown Lombardi Comprehensive Cancer Center](https://onco.cc/institutions/georgetown-lombardi/), [Hospital del Mar / Hospital del Mar Research Institute](https://onco.cc/institutions/hospital-del-mar/), [IEO (European Institute of Oncology)](https://onco.cc/institutions/ieo-milan/), [Institut Jules Bordet](https://onco.cc/institutions/institut-jules-bordet/), [Instituto Alexander Fleming](https://onco.cc/institutions/instituto-alexander-fleming/), [IRCCS Ospedale San Raffaele](https://onco.cc/institutions/san-raffaele/), [Istituto di Candiolo IRCCS (FPO)](https://onco.cc/institutions/candiolo/), [Istituto Oncologico Veneto IRCCS](https://onco.cc/institutions/iov-veneto/), [Mayo Clinic Comprehensive Cancer Center in Florida](https://onco.cc/institutions/mayo-clinic-florida/), [National Taiwan University Hospital](https://onco.cc/institutions/ntuh/), [Orlando Health Cancer Institute](https://onco.cc/institutions/orlando-health-cancer-institute/), [Rosalind and Morris Goodman Cancer Institute, McGill University](https://onco.cc/institutions/mcgill-goodman/), [Tianjin Medical University Cancer Institute and Hospital](https://onco.cc/institutions/tmucih/), [Union Hospital, Tongji Medical College](https://onco.cc/institutions/union-hospital-wuhan/), [Weizmann Institute of Science](https://onco.cc/institutions/weizmann/)
- people: [Aleix Prat](https://onco.cc/people/aleix-prat/), [Andrew Wardley](https://onco.cc/people/andrew-wardley/), [Anna Sapino](https://onco.cc/people/anna-sapino/), [Barbara Bradfield](https://onco.cc/people/barbara-bradfield/), [Binghe Xu](https://onco.cc/people/xu-binghe/), [Carlos Barrios](https://onco.cc/people/barrios-carlos/), [Carlos Caldas](https://onco.cc/people/carlos-caldas/), [Charles E. Geyer Jr.](https://onco.cc/people/charles-geyer/), [Charles M. Perou](https://onco.cc/people/charles-perou/), [Clifford A. Hudis](https://onco.cc/people/clifford-hudis/), [Cristina Saura](https://onco.cc/people/cristina-saura/), [David Cameron](https://onco.cc/people/david-cameron/), [Debu Tripathy](https://onco.cc/people/debu-tripathy/), [Dennis J. Slamon](https://onco.cc/people/dennis-slamon/), [Derrick S. Haslem](https://onco.cc/people/derrick-haslem/), [Donna McKay](https://onco.cc/people/donna-mckay/), [Eleftherios P. Mamounas](https://onco.cc/people/eleftherios-mamounas/), [Eric P. Winer](https://onco.cc/people/eric-winer/), [Eva Ciruelos](https://onco.cc/people/eva-ciruelos/), [Evandro de Azambuja](https://onco.cc/people/evandro-de-azambuja/), [Fei Ma](https://onco.cc/people/ma-fei/), [Gunter von Minckwitz](https://onco.cc/people/gunter-von-minckwitz/), [Helena Earl](https://onco.cc/people/helena-earl/), [Ian E. Krop](https://onco.cc/people/ian-krop/), [Isabel T. Rubio](https://onco.cc/people/isabel-rubio/), [Jame Abraham](https://onco.cc/people/jame-abraham/), [Javier Cortés](https://onco.cc/people/javier-cortes/), [Joaquín Arribas](https://onco.cc/people/joaquin-arribas/), [Jonas Bergh](https://onco.cc/people/jonas-bergh/), [Joohyuk Sohn](https://onco.cc/people/sohn-joohyuk/), [José Baselga](https://onco.cc/people/jose-baselga/), [Kan Yonemori](https://onco.cc/people/yonemori-kan/), [Laura J. Esserman](https://onco.cc/people/laura-esserman/), [Luca Gianni](https://onco.cc/people/luca-gianni/), [Marek Svoboda](https://onco.cc/people/marek-svoboda/), [Martine Piccart](https://onco.cc/people/martine-piccart/), [Michael Gnant](https://onco.cc/people/michael-gnant/), [Monica Morrow](https://onco.cc/people/monica-morrow/), [Nadia Harbeck](https://onco.cc/people/nadia-harbeck/), [Nancy U. Lin](https://onco.cc/people/nancy-lin/), [Norman Wolmark](https://onco.cc/people/norman-wolmark/), [Priya Rastogi](https://onco.cc/people/priya-rastogi/), [Rashmi K. Murthy](https://onco.cc/people/rashmi-murthy/), [Rebecca Dent](https://onco.cc/people/rebecca-dent/), [Rupert Bartsch](https://onco.cc/people/rupert-bartsch/), [Sandra M. Swain](https://onco.cc/people/sandra-swain/), [Sara A. Hurvitz](https://onco.cc/people/sara-hurvitz/), [Sara López-Tarruella](https://onco.cc/people/sara-lopez-tarruella/), [Sara M. Tolaney](https://onco.cc/people/sara-tolaney/), [Shanu Modi](https://onco.cc/people/shanu-modi/), [Shinji Ohno](https://onco.cc/people/ohno-shinji/), [Sibylle Loibl](https://onco.cc/people/sibylle-loibl/), [Sung-Bae Kim](https://onco.cc/people/kim-sung-bae/), [Sunil Lakhani](https://onco.cc/people/sunil-lakhani/), [Suzette Delaloge](https://onco.cc/people/suzette-delaloge/), [Tari A. King](https://onco.cc/people/tari-king/), [Thomas Bachelot](https://onco.cc/people/thomas-bachelot/), [Yeon Hee Park](https://onco.cc/people/park-yeon-hee/)
- bottlenecks: [Biomarkers are not validated or standardised](https://onco.cc/bottlenecks/b-biomarker-validation/), [Knowledge reaches practice too slowly](https://onco.cc/bottlenecks/b-knowledge-diffusion/), [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [The brain: barrier and sanctuary](https://onco.cc/bottlenecks/b-brain-delivery/), [Wrong doses](https://onco.cc/bottlenecks/b-dose-optimisation/)
- collections: [Living Beyond Breast Cancer](https://onco.cc/collections/src-lbbc/), [Susan G. Komen](https://onco.cc/collections/susan-g-komen/)
- biomarkers: [HER2 IHC 3+ (HER2-positive by immunohistochemistry)](https://onco.cc/biomarkers/her2-ihc-3-plus/), [HER2 ISH amplified (ERBB2 gene amplification)](https://onco.cc/biomarkers/her2-ish-amplified/)

---
JSON: https://onco.cc/api/v1/entities/breast-her2-positive.json